Literature DB >> 19142758

Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients.

Ramon C Hermida1, Diana E Ayala, Luisa Chayan, Artemio Mojon, Jose R Fernandez.   

Abstract

Previous studies established that a single daily dose of olmesartan remains effective for the entire 24 h without alteration of the day-night blood pressure (BP) pattern. On the other hand, the administration of valsartan or telmisartan at bedtime, as opposed to upon wakening, improves the sleep-time relative BP decline toward a greater dipper pattern without loss of 24 h efficacy. Yet to be determined is whether this administration-time-dependent efficacy is a class-related feature, characteristic of all angiotensin-receptor-blocker (ARB) medications. We studied 123 grade 1 and 2 hypertensive patients, 46.6+/-12.3 yrs of age, randomly assigned to receive olmesartan (20 mg/day) as a monotherapy either upon awakening or at bedtime for three months. BP was measured by ambulatory monitoring for 48 consecutive hours before and after treatment. The 24 h BP reduction was similar for both treatment times. Administration of olmesartan at bedtime, however, was significantly more efficient than morning administration in reducing the nocturnal BP mean. The sleep-time relative BP decline was slightly reduced with olmesartan ingestion upon awakening but significantly increased with ingestion at bedtime, thus reducing the prevalence of non-dipping from baseline by 48%. Olmesartan administration at bedtime, as opposed to in the morning, improved the awake/asleep BP ratio toward a greater dipper pattern without loss of 24 h efficacy. Nocturnal BP regulation was significantly better achieved with bedtime as compared to morning dosing of olmesartan. These effects are comparable to those previously reported for valsartan and telmisartan, thus suggesting that they may be class-related features of ARB medications in spite of differences in their half-life kinetics. These administration-time-dependent effects should be taken into account when prescribing ARB medications for treatment of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19142758     DOI: 10.1080/07420520802548135

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  24 in total

1.  Appropriateness of timing of drug administration in electronic prescriptions.

Authors:  Arwa Hassan; Walter E Haefeli
Journal:  Pharm World Sci       Date:  2010-01-10

Review 2.  Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Juan J Crespo; María T Ríos; Ana Moyá; Francesco Portaluppi
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

Review 3.  Chronotherapy for Hypertension.

Authors:  N P Bowles; S S Thosar; M X Herzig; S A Shea
Journal:  Curr Hypertens Rep       Date:  2018-09-28       Impact factor: 5.369

Review 4.  Timing is important in medication administration: a timely review of chronotherapy research.

Authors:  Gagandeep Kaur; Craig Phillips; Keith Wong; Bandana Saini
Journal:  Int J Clin Pharm       Date:  2013-01-18

Review 5.  Chronotherapy improves blood pressure control and reduces vascular risk in CKD.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; Artemio Mojón; José R Fernández; Juan J Crespo; Ana Moyá; María T Ríos; Francesco Portaluppi
Journal:  Nat Rev Nephrol       Date:  2013-04-23       Impact factor: 28.314

Review 6.  Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease?

Authors:  Rupal Mehta; Paul E Drawz
Journal:  Curr Hypertens Rep       Date:  2011-10       Impact factor: 5.369

Review 7.  Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Francesco Portaluppi
Journal:  Hypertens Res       Date:  2015-12-10       Impact factor: 3.872

8.  A cyclic fluctuation model for 24-h ambulatory blood pressure monitoring in Chinese patients with mild to moderate hypertension.

Authors:  Yu-cheng Sheng; Kun Wang; Ling Xu; Juan Yang; Ying-chun He; Qing-shan Zheng
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

Review 9.  Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.

Authors:  Harikrishna Makani; Sripal Bangalore; Azhar Supariwala; Jorge Romero; Edgar Argulian; Franz H Messerli
Journal:  Eur Heart J       Date:  2013-08-21       Impact factor: 29.983

Review 10.  Nocturnal medications dosing: does it really make a difference in blood pressure control among patients with chronic kidney disease?

Authors:  Salman Rasheed Mallick; Mahboob Rahman
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.